Unum Therapeutics (NASDAQ:UMRX) Downgraded to “Hold” at Zacks Investment Research
According to Zacks, “Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company’s program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. “
A number of other brokerages have also recently issued reports on UMRX. SunTrust Banks dropped their price objective on Unum Therapeutics to $6.00 and set a “buy” rating on the stock in a report on Wednesday, July 3rd. ValuEngine raised Unum Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Cowen reaffirmed a “hold” rating on shares of Unum Therapeutics in a report on Monday, August 12th. Wedbush lowered their price target on Unum Therapeutics from $20.00 to $13.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. They noted that the move was a valuation call. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Unum Therapeutics in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $12.40.
Unum Therapeutics (NASDAQ:UMRX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.05. The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $3.10 million. Unum Therapeutics had a negative return on equity of 75.60% and a negative net margin of 340.49%. Equities analysts forecast that Unum Therapeutics will post -1.24 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP purchased a new stake in shares of Unum Therapeutics in the 2nd quarter valued at about $62,000. Acadian Asset Management LLC raised its holdings in shares of Unum Therapeutics by 134.8% in the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock valued at $85,000 after acquiring an additional 18,717 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Unum Therapeutics in the 1st quarter valued at about $85,000. Jane Street Group LLC purchased a new stake in shares of Unum Therapeutics in the 2nd quarter valued at about $132,000. Finally, Paloma Partners Management Co purchased a new stake in shares of Unum Therapeutics in the 2nd quarter valued at about $227,000. 41.95% of the stock is currently owned by hedge funds and other institutional investors.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Featured Story: Trading based on a resistance level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.